Price will sustain with few shorts.
Ongoing and can join anytime.
CytRx intends to discuss a pathway for the registration of aldoxorubicin for KS with the FDA, provided that preliminary Phase 2 data are positive.
Linker Compound Offers A Promising Investment by Fusion Research for a very thorough explanation and comparison.
The competition drug for CYTR is Doxorubicin which is a highly toxic drug that can cause side effects and CYTRX offers Aldoxorubicin and that should help in this area after all it's the main reason for its development. Since doxorubicin has been known to cause heart damage in cancer patients, doxorubicin has a limit on the cumulative amount of drug the patient can receive.
If trials continue as successfully as they have, Investors should see aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find an immediate market with a monstrous revenue stream.
CYTRx is a better proposition on AIDS & BRAIN CANCER Pivotal trials under US FDA - SPA actually CYTR did went up to $9 but street wanted it cheap.
under a Special Protocol Assessment, or “SPA,” granted by the U.S. Food and Drug Administration, or the “FDA,” a potential pivotal Phase 3 global trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed following treatment with chemotherapy. The Company also is initiating Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites
If CytRx delivers positive results for its three clinical trials and manages to get FDA approval for its blockbuster product aldoxorubicin, the share price could run substantially higher. The fact that CytRx holds the exclusive worldwide rights to aldoxorubicin only adds to the appeal of this under-followed biopharmaceutical play
Positive results from the Phase 2 trial will support CytRx in pursuing the rapid development of aldoxorubicin for unresectable GBM,” writes Johnson. “This will also allow the company to file for the “breakthrough therapy” designation with the FDA, which is expected to expedite aldoxorubicin’s marketing approval. This will enable CytRx to enhance its presence in the oncology drug market to treat GBM, and strengthen its financial position. The approval of aldoxorubicin for GBM could generate revenue of roughly $300 million during its peak sales period.”
CytRx recently received FDA approval to extend the dosing in a phase 3 clinical trial to evaluate aldoxorubicin as a second-line treatment for soft-tissue sarcomas (STS). The extended dosing could allow CytRx to demonstrate even higher progression-free survival (PFS) efficacy results compared to the phase 2b trial for advanced STS with this drug. The company plans to initiate the phase 3 trial in the first quarter of 2014.
We really had spectacular results in our global phase 2b clinical trial in first-line soft tissue sarcoma. And when I say 'spectacular,' they were highly statistically significant, not just statistically significant... we had great response rates... we saw substantial tumor shrinkage
By reaching an agreement on an SPA, the FDA deems that results from this single Phase 3 clinical trial will be acceptable to support the regulatory approval of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma, with final marketing approval dependent on the results of the trial and other accomplishments